Pathstone Family Office’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | $2.89M | Buy |
41,137
+15,065
| +58% | +$1.06M | 0.02% | 392 |
|
|
2023
Q2 | $2.69M | Buy |
26,072
+1,301
| +5% | +$134K | 0.04% | 267 |
|
|
2023
Q1 | $1.99M | Sell |
24,771
-41,717
| -63% | -$3.35M | 0.03% | 288 |
|
|
2022
Q4 | $3.72M | Buy |
66,488
+14,020
| +27% | +$785K | 0.03% | 338 |
|
|
2022
Q3 | $4.44M | Buy |
52,468
+35,264
| +205% | +$2.98M | 0.04% | 256 |
|
|
2022
Q2 | $1.64M | Sell |
17,204
-3,687
| -18% | -$351K | 0.04% | 239 |
|
|
2022
Q1 | $2.53M | Buy |
20,891
+13,131
| +169% | +$1.59M | 0.06% | 150 |
|
|
2021
Q4 | $1.01M | Buy |
7,760
+2,490
| +47% | +$322K | 0.03% | 335 |
|
|
2021
Q3 | $598K | Buy |
5,270
+1,205
| +30% | +$137K | 0.02% | 452 |
|
|
2021
Q2 | $421K | Buy |
+4,065
| New | +$421K | 0.01% | 533 |
|
|
2021
Q1 | – | Sell |
-541
| Closed | -$49K | – | 865 |
|
|
2020
Q4 | $49K | Buy |
541
+535
| +8,917% | +$48.5K | ﹤0.01% | 510 |
|
|
2020
Q3 | $0 | Hold |
6
| – | – | ﹤0.01% | 864 |
|
|
2020
Q2 | $0 | Hold |
6
| – | – | ﹤0.01% | 797 |
|
|
2020
Q1 | $0 | Buy |
+6
| New | – | ﹤0.01% | 779 |
|
|
2019
Q2 | – | Sell |
-39
| Closed | -$2K | – | 712 |
|
|
2019
Q1 | $2K | Sell |
39
-2,238
| -98% | -$115K | ﹤0.01% | 760 |
|
|
2018
Q4 | $116K | Buy |
+2,277
| New | +$116K | 0.03% | 116 |
|
|
2017
Q3 | – | Sell |
-3,000
| Closed | -$118K | – | 226 |
|
|
2017
Q2 | $118K | Sell |
3,000
-30
| -1% | -$1.18K | 0.05% | 142 |
|
|
2017
Q1 | $95K | Buy |
+3,030
| New | +$95K | 0.05% | 135 |
|
|
2013
Q3 | – | Sell |
-126
| Closed | -$1K | – | 345 |
|
|
2013
Q2 | $1K | Buy |
+126
| New | +$1K | ﹤0.01% | 352 |
|